Open navigation
purple-dna

RaNA Therapeutics to Present at BIO CEO & Investor Conference and Leerink Partners Global Healthcare Conference

Read More

Merck Joins $55M Wager on RaNA Therapeutics, Pushing Frontier With RNA Medicines

Read More

RaNA CEO Renaud Turns To A Former Backer To Lead $55M Series B

Read More

RaNA Therapeutics is pioneering the discovery of a novel approach that targets RNA within cells in the body to selectively activate protein expression.

RaNA’s oligonucleotide platform capabilities include blocking gene-repressive complexes and stabilizing mRNA half-life to upregulate, or increase, the level of important proteins in the body to treat or prevent disease.

LEARN ABOUT OUR PLATFORM

Meet the RaNA Team

We are innovative and fearless, taking bold steps and pushing boundaries to pioneer groundbreaking science.

MANAGEMENT TEAM BOARD OF DIRECTORS SCIENTIFIC ADVISORY BOARD BE FEARLESS